On March 2, 2026 OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE), reported a targeted realignment of its R&D portfolio to reinforce execution of its previously announced 2026-2028 strategic plan. The Company will pause development of OSE‑230, allowing OSE to focus its resources on late‑stage, high‑potential assets lusvertikimab (OSE‑127) and Tedopi. These two assets are expected to generate multiple clinical catalysts over the next three years.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

At the same time, Boehringer Ingelheim has decided to discontinue BI 770371 in MASH following completion of an exploratory Phase 2 study that did not demonstrate efficacy in this indication. The treatment was well tolerated with a manageable safety profile, and this indication‑specific decision does not affect the molecule’s ongoing oncology development, where multiple Phase 1 studies continue as planned.

Marc Le Bozec, Chief Executive Officer of OSE Immunotherapeutics, commented: "These decisions mark a disciplined evolution of our portfolio. By stepping away from selected early‑stage programs which were not expected to generate meaningful value inflection points over our three-year strategic program, we are concentrating our resources where OSE can create the greatest value in the near term. This strengthened focus enhances our ability to deliver late‑stage clinical progress, secure meaningful partnerships, and accelerate Tedopi and lusvertikimab, the cornerstone assets of our 2026–2028 roadmap. In parallel, the Company continues to actively assess financing options to fully support the progression of its late‑stage clinical portfolio."

OSE‑230: Strategic Focus on Near‑Term Value

OSE Immunotherapeutics has decided to pause OSE‑230 as part of its ongoing portfolio prioritization and disciplined capital allocation strategy. This decision, following an amendment to the collaboration agreement with the development partner in December 2025, reflects the Company’s focus on advancing its most mature clinical programs and near‑term value drivers. OSE Immunotherapeutics will continue to assess opportunities to maximize value across its broader pipeline.

BI 770371: Partner‑Led Realignment, Focus on Oncology

Although BI 770371 was well tolerated with a manageable safety profile, Boehringer Ingelheim has decided to discontinue development of BI 770371 for people with liver cirrhosis caused by MASH after an exploratory Phase 2 study (NCT06675929) did not demonstrate efficacy to support further development in this indication.

This MASH decision does not impact BI 770371’s ongoing oncology development, which was the initial and lead program of the OSE and Boehringer Ingelheim collaboration, where the mechanism of action is distinct and multiple Phase 1 programs remain active and progressing as planned.

Additional Pipeline Prioritization

As part of the Company’s ongoing portfolio streamlining, OSE will also discontinue exploratory research activities related to the CLEC‑1 programme in oncology, an early myeloid checkpoint target still at preclinical stage. While scientifically promising, CLEC‑1 in oncology does not fall within the Company’s immediate clinical or partnership priorities. This decision further aligns OSE’s portfolio with its late‑stage value creation strategy.

Expected Value Inflection Points over OSE’s three-year strategic plan (2026-2028)

On January 29, 20261, OSE announced the selection of chronic pouchitis and hidradenitis suppurativa (HS) as the next potential targeted indications for lusvertikimab (OSE‑127), based on strong IL‑7R‑driven biological rationale. In parallel, the Company is developing a subcutaneous formulation to advance lusvertikimab in ulcerative colitis (UC) and completing the Tedopi Phase 3 in NSCLC.

This 2026-2028 strategic plan comes with significant expected value inflection points, including2:

Q2 2026: Tedopi Ovarian Cancer Investigator Sponsored Trial Phase 2 read-out
Q3 2026: Tedopi NSCLC Pivotal Phase 3 interim futility analysis
H2 2026: Tedopi 2L NSCLC combo Investigator Sponsored Trial Phase 2 read-out
H1 2027: Lusvertikimab sub-cutaneous formulation readiness
H2 2027: Possible start of Ulcerative Colitis Phase 2b/3
Q1 2028: Tedopi NSCLC Pivotal Phase 3 read-out
2028: Lusvertikimab 1st Phase 2 read-out in pouchitis or hidradenitis suppurativa.

(Press release, OSE Immunotherapeutics, MAR 2, 2026, View Source [SID1234663199])